Show
Sort by
-
Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years : final 96-week results of the NEAT022 study
-
Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies
-
Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study